Aurinia Pharmaceuticals (AUPH) Receivables - Other (2019 - 2020)
Aurinia Pharmaceuticals' (AUPH) quarterly Receivables - Other came in at $51000.0 in Q4 2020, down 75.12% YoY from $205000.0 in Q1 2020, and down 75.12% on a QoQ basis from $205000.0 in Q4 2019.
Powered by 
Analysis
Aurinia Pharmaceuticals (AUPH) Receivables - Other (2019 - 2020) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 2 years of Receivables - Other data on file, last reported at $51000.0 in Q4 2020.
- Quarterly Receivables - Other fell 75.12% year-over-year to $51000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $51000.0 (down 75.12% YoY) and the FY2020 annual result came in at $51000.0, down 75.12% from the prior year.
- Receivables - Other eased to $51000.0 in Q4 2020, from $205000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $205000.0 in Q4 2019 to a low of $51000.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.10 Bn | 1.66 Bn | 76.67 Mn |